Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] A new threat to obesity: vanity sizing
- [Correspondence] The need for a type 1 diabetes scorecard
- [Editorial] Kidney disease at the forefront of the global health agenda
- [Corrections] Correction to Lancet Diabetes Endocrinol 2025; 13: 175–76
- [Comment] The promise and pitfalls of “Make America Healthy Again”
- [Comment] A step towards more physiological glucocorticoid dosing in congenital adrenal hyperplasia
- [Correspondence] What does renal failure teach us about our National Health System?
- [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: e2–11
- [Articles] Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials
- [Comment] Bodyweight loss and remission of type 2 diabetes
- [Correspondence] Type 1 diabetes screening: need for ethical, equity, and health systems perspective
- [Corrections] Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62
- [Correspondence] Mpox and diabetes: a needed public health research agenda
- [Comment] Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2024
- [Comment] Vitamin D and acute respiratory infections: a definitive answer?
- [Articles] Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data
- [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 523–34
- [Comment] When glucose time in range is not tight, is it lax? Considering new terminology for CGM targets
- [Corrections] Correction to Lancet Diabetes Endocrinol 2025; 13: 47–56
- [Articles] Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial